Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection

Tuberculosis Clinical Trial

— NextGen  

Official title:

Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02512939
• Other study ID #: Next gen
• Status: Completed
• Phase: N/A
• Start date: July 2015
• Est. completion date: November 30, 2016

Study information

• Verified date: May 2023
• Source: University College, London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the next generation of blood tests for latent TB infection, which may be able to indicate how treatment is working as well as in diagnosis infection.

Description:

Currently available blood tests for latent tuberculosis infection (LTBI) identify people who have been previously infected with M. tuberculosis. Whilst they are sensitive and specific, they cannot be used to monitor the effectiveness of treatment for LTBI. New blood tests ("fourth generation Quantiferon tests") give a more complete measurement of the workings of the immune system, which may be useful to show whether treatment is working. These new tests have not yet been evaluated in clinical practice, so their usefulness in identifying people at highest risk of TB disease and monitoring treatment is unknown.

Mass gatherings, such as the annual Hajj pilgrimage, may encourage the spread of infectious diseases, including respiratory infections such as influenza, respiratory syncytial virus, and possibly also tuberculosis. However, the risk of TB infection during the Hajj has not been reliably measured. It is important to measure this risk so that pilgrims can be given suitable advice about preventing infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 675
• Est. completion date: November 30, 2016
• Est. primary completion date: November 30, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Contacts: Adult (aged 16 years or older) contacts of smearpositive pulmonary TB patients attending participating TB clinics or primary care centres for screening will be invited to take part. Contacts will include all individuals with a cumulative duration of exposure of greater than eight hours to the relevant index case in a confined space during the period of infectiousness (prior to initiation of treatment). Patients with active TB: Newly diagnosed, microbiologically confirmed tuberculosis disease (pulmonary or extrapulmonary) attending participating TB clinics or primary care centres. Hajj pilgrims: Individuals arranging travel to Saudi Arabia for the Hajj through participating tour operators.

Exclusion Criteria:

• Contacts: Active TB disease. Individuals who are unable to give informed consent. Children aged under 16 years.

TB cases: Individuals who are unable to give informed consent. Children aged under 16 years.

Hajj pilgrims: Active TB disease. Any health indication which would prevent travel to Saudi Arabia. Individuals who are unable to give informed consent. Children aged under 16 years.

Related Conditions & MeSH terms

• Latent Tuberculosis
• Tuberculosis

Intervention

Procedure:
• blood test, not yet marketed, no trade name
blood test using the new TB diagnostic test

Locations

Country	Name	City	State
United Kingdom	Barts NHS Trust	London
United Kingdom	Ealing Hospital	London
United Kingdom	North Middlesex Hospital	London
United Kingdom	Northwick Park Hospital	London
United Kingdom	West Middlesex Hospital NHS Trust	London

Sponsors (2)

Lead Sponsor	Collaborator
University College, London	Public Health England

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	assess prognostic ability of blood test by assessing development of active TB disease compared to the current gold standard	assess prognostic ability of blood test by assessing development of active TB disease.	1 year
Secondary	assess the sensitivity of new blood tests for detecting TB infection in patients with active TB disease compared to teh current godl standard	estimate the sensitivity of new blood tests for detecting TB infection in patients with active TB disease	1 year
Secondary	estimate the risk of infection with M. tuberculosis and other respiratory pathogens amongst UK pilgrims undertaking the Hajj.	estimate the risk of infection with M. tuberculosis and other respiratory pathogens amongst UK pilgrims undertaking the Hajj.	1 year